Koen Van Besien to Rituximab
This is a "connection" page, showing publications Koen Van Besien has written about Rituximab.
Connection Strength
1.023
-
Prophylactic rituximab prevents EBV PTLD in haplo-cord transplant recipients at high risk. Leuk Lymphoma. 2019 07; 60(7):1693-1696.
Score: 0.619
-
A renaissance for autologous transplantation in follicular lymphoma? Leuk Lymphoma. 2019 01; 60(1):3-5.
Score: 0.148
-
Myasthenia gravis, an autoimmune manifestation of lymphoma and lymphoproliferative disorders: case reports and review of literature. Leuk Lymphoma. 2012 Mar; 53(3):371-80.
Score: 0.093
-
Fatal CMV pneumonitis in a lymphoma patient treated with rituximab. Am J Hematol. 2009 Sep; 84(9):614-6.
Score: 0.080
-
Phase II study of immunomodulation with granulocyte-macrophage colony-stimulating factor, interleukin-2, and rituximab following autologous stem cell transplant in patients with relapsed or refractory lymphomas. Leuk Lymphoma. 2010 Jul; 51(7):1241-50.
Score: 0.021
-
The role of cytotoxic therapy with hematopoietic stem cell transplantation in the treatment of follicular lymphoma: an evidence-based review. Biol Blood Marrow Transplant. 2010 Apr; 16(4):443-68.
Score: 0.021
-
Multicenter analysis of 80 solid organ transplantation recipients with post-transplantation lymphoproliferative disease: outcomes and prognostic factors in the modern era. J Clin Oncol. 2010 Feb 20; 28(6):1038-46.
Score: 0.021
-
Impact of pre-transplant rituximab on survival after autologous hematopoietic stem cell transplantation for diffuse large B cell lymphoma. Biol Blood Marrow Transplant. 2009 Nov; 15(11):1455-64.
Score: 0.020